- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05355714
High Intensity Ultrasound for the Treatment of Upper Inner Arm Skin Laxity
A Single Center, Blinded, Split-Body, Randomized Clinical Trial of High Intensity Ultrasound for the Treatment of Upper Inner Arm Skin Laxity
Study Overview
Detailed Description
This is a prospective, single-center, blinded, split-body site, randomized, controlled clinical trial. The study will consist of 15 subjects who will be treated with Sofwave® on one upper medial arm and Ultherapy® to the contralateral upper medial arm for treatment of skin laxity.
Upon enrollment and after a thorough review of the inclusion and exclusion criteria as well as obtaining written and informed consent, each subject will be randomized to have either their right upper inner arm or left upper inner arm treated with Sofwave®, and the contralateral arm will be treated with Ultherapy®. The treatment area is defined as the upper inner medial arm (Appendix A). This area, which abuts the axilla, was chosen as the treatment zone because it is primarily composed of skin on superficial fascia without excessive amounts of adipose tissue. Conversely, the posterior arm typically has extra adipose tissue which would confound the study's measurements
At every visit, the subject's medical history and concomitant medications will be reviewed in detail and weight will be recorded. Additionally, at every treatment and follow-up visit, each subject will have standardized, high-resolution digital photographs taken (Appendix D). Prior to the treatment and at all follow-up visits, the blinded investigator will complete the Upper Inner Arm Visual Crepiness/Laxity Grading Scale, Point of Maximal Upper Arm Skin Laxity Diameter and Circumference Measurements, and skin firmness and elasticity measurements using a Cutometer® Dual MPA 580 (Courage+Khazaka electronic GmbH; Köln, Germany).
Subjects may be treated on the same day that they are screened and provide informed consent. If applicable, a urine pregnancy test will be obtained prior to each treatment. Anesthesia will be provided per physician discretion; options include topical anesthetic (23% lidocaine/7% tetracaine) for 1-hour, oral valium, and/or nitrous oxide. Immediately before treatment, the upper arm treatment zones should be mapped and subsequently cleansed with Hibiclens® (chlorhexidine gluconate solution 4%; Mölnlycke Health Care AB; Gothenburg, Sweden). The arm randomized to receive Sofwave® will receive one treatment session during which the treatment area will receive 3-4 passes. The arm randomized to receive Ultherapy® will receive one treatment session during which the treatment area will receive 1 pass with the 4.0 MHz, 4.5-mm-depth transducer and a subsequent pass with the 7.0 MHz, 3.0-mm-depth transducer. Treatment start and end times will be recorded.
After each treatment session and during all follow-up visits, the treating physician will evaluate the subjects for any procedure-related side effects and adverse events. The subjects will rate their pain. At each follow-up visit, a Physician Global Aesthetic Improvement Scale (PGAIS), Subject Global Aesthetic Improvement Scale (SGAIS), and subject satisfaction questionnaire will be completed.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andrea Pacheco
- Phone Number: 858 657 1004
- Email: APacheco@CLDerm.com
Study Locations
-
-
California
-
San Diego, California, United States, 92121
- Recruiting
- Cosmetic Laser Dermatology
-
Contact:
- Sherif Mikhail, MD
- Phone Number: 858-657-1004
- Email: SMikhail@clderm.com
-
Principal Investigator:
- Monica Boen, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
a) Male or female subjects > 35 years of age and < 70 years of age b) Subjects in good general health based on investigator's judgment and medical history c) Upper inner arm skin laxity that improves when the skin of the upper inner arm is stretched or lifted superiorly d) Moderate to severe upper inner arm skin crepiness/laxity based on the Upper Inner Arm Visual Crepiness/Laxity Grading Scale (Appendix B) e) Must be willing to give and sign an informed consent form and photographic release form f) Must have a stable body weight for at least six (6) months prior to study entry g) Must be willing to maintain usual sun exposure, diet, and exercise routines for the duration of the study h) Must agree to avoid tanning or use of sunless tanner during the entire course of the study i) Negative urine pregnancy test result at the time of study entry (if applicable) j) For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.
- A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation.
- Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g., condoms and spermicide), abstinence, and/or vasectomy of partner with a documented second acceptable method of birth control, should the subject become sexually active.
k) Must be willing to comply with study treatments and complete the entire course of the study
Exclusion Criteria:
- Liposuction to bilateral upper arms during the 12-month period prior to study treatment or any time during the course of the study
- Mesotherapy; dermal fillers, biostimulatory injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery (i.e., brachyplasty) during the 12-month period before study treatment
- Any investigational treatment of skin crepiness/laxity of the upper arms during the 12-month period before the study treatment
- Creams/cosmeceuticals and/or home therapies to prevent or treat skin laxity during the four-week period before study treatment
- Subjects with scarring in the treatment areas
- History of thrombosis, post-thrombosis syndrome, or any vascular disorder of the bilateral upper extremities
- Any history of bleeding or coagulation disorders
- Subjects with tattoos or permanent implants in the treatment areas
- Subjects with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study
- Subjects with a history of or presence of any skin condition/disease (including but not limited to any visible rash, atopic dermatitis, psoriasis, actinic keratoses, keratinocyte carcinoma, melanoma, etc.) in the treatment area that might interfere with the diagnosis or evaluation of study parameters
- Subjects with an active bacterial, viral, or fungal infection of the treatment areas
- Subjects who spray tanned or used sunless tanners in the treatment areas four (4) weeks prior to study treatment
- History of lidocaine sensitivity deemed by the investigator to preclude the subject from enrolling into the study
- Subjects planning any cosmetic procedure to the treatment areas during the study period, other than the treatment that will be performed by the investigator
- Presence of incompletely healed wound(s) in the treatment area
- Subject who is on an immunosuppressant or has an autoimmune condition
- Female subjects who are pregnant, planning a pregnancy, or breast feeding during the study
- Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sofwave
|
High-Frequency Non-Focused Ultrasound Device
|
OTHER: Ultherapy
|
Microfocused Ultrasound with Visualization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Upper Inner Arm Visual Skin Crepiness and Laxity
Time Frame: Screening to One Month Post-Treatment
|
Upper Inner Arm Visual Skin Crepiness/Laxity Grading Scale completed by blinded investigator
|
Screening to One Month Post-Treatment
|
Upper Inner Arm Visual Skin Crepiness and Laxity
Time Frame: Screening to Three Months Post-Treatment
|
Upper Inner Arm Visual Skin Crepiness/Laxity Grading Scale completed by blinded investigator
|
Screening to Three Months Post-Treatment
|
Upper Arm Circumference
Time Frame: Screening to One Month Post-Treatment
|
Blinded Investigator Measurement of Point of Maximal Upper Arm Skin Laxity and Circumference
|
Screening to One Month Post-Treatment
|
Upper Arm Circumference
Time Frame: Screening to Three Months Post-Treatment
|
Blinded Investigator Measurement of Point of Maximal Upper Arm Skin Laxity and Circumference
|
Screening to Three Months Post-Treatment
|
Upper Arm Firmness
Time Frame: Screening to One Month Post-Treatment
|
Blinded Investigator Measurement of Skin Firmness
|
Screening to One Month Post-Treatment
|
Upper Arm Firmness
Time Frame: Screening to Three Months Post-Treatment
|
Blinded Investigator Measurement of Skin Firmness
|
Screening to Three Months Post-Treatment
|
Upper Arm Elasticity
Time Frame: Screening to One Month Post-Treatment
|
Blinded Investigator Measurement of Skin Elasticity
|
Screening to One Month Post-Treatment
|
Upper Arm Elasticity
Time Frame: Screening to Three Months Post-Treatment
|
Blinded Investigator Measurement of Skin Elasticity
|
Screening to Three Months Post-Treatment
|
Physician Global Aesthetic Improvement Scale (PGAIS)
Time Frame: One Month Post-Treatment
|
Assessment of overall change in treatment area by blinded investigator
|
One Month Post-Treatment
|
Physician Global Aesthetic Improvement Scale (PGAIS)
Time Frame: Three Months Post-Treatment
|
Assessment of overall change in treatment area by blinded investigator
|
Three Months Post-Treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject Global Aesthetic Improvement Scale (SGAIS)
Time Frame: One Month Post-Treatment
|
Assessment of overall change in treatment area by subject
|
One Month Post-Treatment
|
Subject Global Aesthetic Improvement Scale (SGAIS)
Time Frame: Three Months Post-Treatment
|
Assessment of overall change in treatment area by subject
|
Three Months Post-Treatment
|
Subject Satisfaction Questionnaire
Time Frame: One Month Post-Treatment
|
Subject degree of satisfaction with results of treatment
|
One Month Post-Treatment
|
Subject Satisfaction Questionnaire
Time Frame: Three Months Post-Treatment
|
Subject degree of satisfaction with results of treatment
|
Three Months Post-Treatment
|
Subject Pain Score
Time Frame: Day of Treatment
|
Subject Assessment of Pain During Treatment
|
Day of Treatment
|
Erythema
Time Frame: Day of Treatment
|
Treating Investigator Evaluation of Erythema
|
Day of Treatment
|
Erythema
Time Frame: One Month Post-Treatment
|
Treating Investigator Evaluation of Erythema
|
One Month Post-Treatment
|
Erythema
Time Frame: Three Months Post-Treatment
|
Treating Investigator Evaluation of Erythema
|
Three Months Post-Treatment
|
Edema
Time Frame: Day of Treatment
|
Treating Investigator Evaluation of Edema
|
Day of Treatment
|
Edema
Time Frame: One Month Post-Treatment
|
Treating Investigator Evaluation of Edema
|
One Month Post-Treatment
|
Edema
Time Frame: Three Months Post-Treatment
|
Treating Investigator Evaluation of Edema
|
Three Months Post-Treatment
|
Dyspigmentation
Time Frame: Day of Treatment
|
Treating Investigator Evaluation of Dyspigmentation
|
Day of Treatment
|
Dyspigmentation
Time Frame: One Month Post-Treatment
|
Treating Investigator Evaluation of Dyspigmentation
|
One Month Post-Treatment
|
Dyspigmentation
Time Frame: Three Months Post-Treatment
|
Treating Investigator Evaluation of Dyspigmentation
|
Three Months Post-Treatment
|
Ulceration
Time Frame: Day of Treatment
|
Treating Investigator Evaluation of Ulceration/Erosion
|
Day of Treatment
|
Ulceration
Time Frame: One Month Post-Treatment
|
Treating Investigator Evaluation of Ulceration/Erosion
|
One Month Post-Treatment
|
Ulceration
Time Frame: Three Months Post-Treatment
|
Treating Investigator Evaluation of Ulceration/Erosion
|
Three Months Post-Treatment
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Sofwave-Ultherapy-2021-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Laxity
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Merz North America, Inc.Ulthera, IncCompletedMild to Moderate Skin Laxity Under the Chin | Mild to Moderate Skin Laxity on NeckUnited States
-
Apsara Medical CorporationCompleted
-
Ulthera, IncCompletedSkin Laxity of the décolletéUnited States
-
Ulthera, IncUniversity of Texas Southwestern Medical CenterCompletedMild to Moderate Skin Laxity on Cheek | Mild to Moderate Skin Laxity on Upper Neck | Mild to Moderate Subcutaneous Fat on Cheek | Mild to Moderate Subcutaneous Fat on Upper Neck
-
Derming SRLCompletedFace Skin LaxityItaly
-
Nashville Centre for Laser and Facial SurgeryBausch HealthUnknownFacial Skin Laxity
-
Ulthera, IncCompletedFacial Skin LaxityUnited States
-
Endo PharmaceuticalsCompletedLaxity; Skin | Cellulite | Edematous Fibrosclerotic PanniculopathyUnited States
Clinical Trials on Sofwave
-
Sofwave Medical LTDCompleted
-
Sofwave Medical LTDRecruiting
-
Sofwave Medical LTDCompletedWrinkle | Skin Laxity | Brow LiftingUnited States
-
Sofwave Medical LTDCompletedSkin LaxityUnited States
-
Sofwave Medical LTDCompleted
-
Sofwave Medical LTDEnrolling by invitationWrinkle | RhytidesUnited States
-
Sofwave Medical LTDCompletedAcne Scars - Mixed Atrophic and HypertrophicUnited States